TNF and rheumatoid arthritis: In contrast to this view in a recent meta analysis study it has been shown thatan increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated 12 weeks with two anti-TNF antibodies (infliximab and adalimumab) [79].